DOCSLIB.ORG

Inner 32 Arbitrage Fund

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inner 32 Arbitrage Fund Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata Arbitrage Fund o i L g (An open ended scheme investing in arbitrage opportunities.) h Riskometer Investors understand that their principal As on 31st January 2021 PORTFOLIO will be at Low Risk % to % to NAV % to % to NAV Company name Company name INVESTMENT STYLE NAV Derivative NAV Derivative The scheme invests in equity and equity related instruments that tries Hedge Positions 67.44 -67.74 Berger Paints India Ltd. 0.25 -0.25 to take advantage of the difference in prices of a security in the cash ICICI Bank Ltd. 1.90 -1.91 The Ramco Cements Ltd. 0.24 -0.24 segment and derivatives segment by turning market volatility to its Housing Development Finance Corporation Ltd. 1.90 -1.91 Bajaj Finance Ltd. 0.23 -0.23 Tata Steel Ltd. 1.73 -1.74 Indraprastha Gas Ltd. 0.22 -0.22 advantage. Bharti Airtel Ltd. 1.73 -1.74 Zee Entertainment Enterprises Ltd. 0.21 -0.21 Axis Bank Ltd. 1.71 -1.72 Mahanagar Gas Ltd. 0.20 -0.20 INVESTMENT OBJECTIVE ITC Ltd. 1.66 -1.67 Petronet Lng Ltd. 0.19 -0.19 State Bank Of India 1.63 -1.64 Shriram Transport Finance Co Ltd. 0.18 -0.18 The investment objective of the Scheme is to seek to generate Sun Pharmaceutical Industries Ltd. 1.57 -1.56 Torrent Power Ltd. 0.17 -0.17 reasonable returns by investing predominantly in arbitrage Asian Paints (India) Ltd. 1.57 -1.58 Aarti Industries Ltd. 0.17 -0.17 opportunities in the cash and derivatives segments of the equity Adani Ports And Special Economic Zone Ltd. 1.49 -1.50 Power Finance Corporation Ltd. 0.14 -0.15 Tech Mahindra Ltd. 1.40 -1.41 Upl Ltd. 0.14 -0.14 markets and by investing balance in debt and money market HCL Technologies Ltd. 1.40 -1.40 Dr. Lal Path Labs Ltd. 0.13 -0.13 instruments. There is no assurance that the objective of the Scheme Reliance Industries Ltd. 1.34 -1.35 Container Corporation Of India Ltd. 0.12 -0.12 will be realised and the Scheme does not assure or guarantee any Lupin Ltd. 1.33 -1.34 Coal India Ltd. 0.11 -0.11 Divi Laboratories Ltd. 1.30 -1.31 Steel Authority India Ltd. 0.11 -0.11 returns. Maruti Suzuki India Ltd. 1.29 -1.30 Motherson Sumi Systems Ltd. 0.10 -0.10 Larsen & Toubro Ltd. 1.24 -1.25 Gail ( India ) Ltd. 0.09 -0.09 DATE OF ALLOTMENT Hindustan Unilever Ltd. 1.23 -1.24 Gmr Infrastucture Ltd. 0.08 -0.08 Dabur India Ltd. 1.20 -1.20 Manappuram Finance Ltd. 0.07 -0.07 December 18,2018 Titan Company Ltd. 1.12 -1.12 Vodafone Idea Ltd. 0.07 -0.07 Dlf Ltd. 1.00 -1.00 Piramal Enterprises Ltd. 0.06 -0.06 FUND MANAGER Tata Motors Ltd. 1.00 -1.00 ICICI Prudential Life Insurance Company Ltd. 0.06 -0.06 Dr Reddys Laboratories Ltd. 0.98 -0.98 Biocon Ltd. 0.05 -0.05 Sailesh Jain (Managing Since 10-Dec-18 and overall experience of 17 Tata Consultancy Services Ltd. 0.94 -0.95 Godrej Properties Ltd. 0.04 -0.04 years) Nestle India Ltd. 0.92 -0.93 Havells India Ltd. 0.03 -0.03 Eicher Motors Ltd. 0.92 -0.92 Coforge Ltd. 0.03 -0.03 Sbi Life Insurance Company Ltd. 0.90 -0.91 Glenmark Pharmaceuticals Ltd. 0.02 -0.02 BENCHMARK Pidilite Industries Ltd. 0.88 -0.88 Apollo Hospitals Enterprise Ltd. 0.02 -0.02 Bajaj Auto Ltd. 0.86 -0.86 Page Industries Ltd. 0.00 0.00 Nifty 50 Arbitrage Index Vedanta Ltd. 0.84 -0.85 Bosch Ltd. 0.00 0.00 Tata Power Company Ltd. 0.80 -0.81 HDFC Asset Management Company Ltd. 0.00 0.00 NAV Hindalco Industries Ltd. 0.79 -0.79 % to Info Edge (India) Ltd. 0.79 -0.79 Name of the Instrument Ratings Direct - Growth : 11.3708 Cadila Healthcare Ltd. 0.78 -0.79 NAV NTPC Ltd. 0.78 -0.77 Direct - Monthly Dividend : 10.9025 United Spirits Ltd. 0.78 -0.78 Debt Instruments Regular - Growth : 11.1917 Cipla Ltd. 0.77 -0.77 Government Securities 7.41 Regular - Monthly Dividend : 10.7013 Aurobindo Pharma Ltd. 0.75 -0.76 GOI - 6.17% (15/07/2021) SOV 1.21 Mahindra & Mahindra Ltd. 0.75 -0.75 GOI - 7.16% (20/05/2023) SOV 1.11 Bajaj Finserv Ltd. 0.67 -0.67 GOI - 4.48% (02/11/2023) SOV 1.05 FUND SIZE Kotak Mahindra Bank Ltd. 0.67 -0.67 GOI - 6.84% (19/12/2022) SOV 0.79 Tata Consumer Products Ltd. 0.65 -0.65 GOI - 7.32% (28/01/2024) SOV 0.74 Rs. 3334.81 (Rs. in Cr.) NMDC Ltd. 0.65 -0.65 GOI - 7.37% (16/04/2023) SOV 0.70 Grasim Industries Ltd. 0.63 -0.63 GOI - 8.83% (25/11/2023) SOV 0.66 MONTHLY AVERAGE AUM ICICI Lombard General Insurance Co. Ltd. 0.61 -0.61 GOI - 8.08% (02/08/2022) SOV 0.48 Power Grid Corporation Of India Ltd. 0.59 -0.59 GOI - 7.94% (24-05-2021) SOV 0.30 Rs. 3042.60 (Rs. in Cr.) Bharat Petroleum Corporation Ltd. 0.57 -0.58 GOI - 5.09% (13/04/2022) SOV 0.21 Indian Oil Corporation Ltd. 0.56 -0.56 GOI 6.30% 9/4/2023 SOV 0.16 Marico Ltd. 0.53 -0.53 Non-Convertible Debentures/Bonds 7.05 TURN OVER Max Financial Services Ltd. 0.50 -0.50 04.95 % HDFC Ltd. CRISIL- AAA 1.50 07.18 % Nabard CRISIL- AAA 0.78 Portfolio Turnover (Total) 1660.52% Torrent Pharmaceuticals Ltd. 0.49 -0.49 Infosys Ltd. 0.49 -0.49 04.50 % HDFC Ltd. CRISIL- AAA 0.74 Portfolio Turnover (Equity component only) 463.67% Britannia Industries Ltd. 0.49 -0.49 07.00 % HDFC Ltd. CRISIL- AAA 0.62 Shree Cement Ltd. 0.47 -0.48 07.61 % Housing & Urban Development Corporation Ltd. ICRA- AAA 0.47 EXPENSE RATIO** MRF Ltd. 0.47 -0.48 08.60 % LIC Housing Finance Ltd. CRISIL- AAA 0.47 Jsw Steel Ltd. 0.47 -0.47 07.39 % LIC Housing Finance Ltd. CRISIL- AAA 0.47 Direct 0.38 ACC Ltd. 0.47 -0.47 08.20 % HDFC Ltd. CRISIL- AAA 0.46 Regular 1.13 HDFC Life Insurance Co. Ltd. 0.47 -0.47 07.62 % Housing & Urban Development Corporation Ltd. ICRA- AAA 0.31 Canara Bank 0.45 -0.45 07.40 % Power Finance Corporation CRISIL- AAA 0.31 **Note: The rates specified are actual month end expenses charged HDFC Bank Ltd. 0.44 -0.45 06.32 % Rec Ltd. CRISIL- AAA 0.31 as on Jan 31, 2021. The above ratio includes the Service tax on Ultratech Cement Ltd. 0.44 -0.45 08.45 % Sikka Ports And Terminals Ltd. (Mukesh Ambani Group) CRISIL- AAA 0.16 Investment Management Fees. The above ratio excludes, Muthoot Finance Ltd. 0.43 -0.43 08.50 % Rec Ltd. CRISIL- AAA 0.16 proportionate charge (out of maximum 30 bps on daily average net Ambuja Cements Ltd. 0.42 -0.43 07.90 % India Infradebt Ltd. CRISIL- AAA 0.15 assets allowed) in respect sales beyond T-30 cities assets, wherever Colgate-Palmolive India Ltd. 0.42 -0.42 07.24 % LIC Housing Finance Ltd. CRISIL- AAA 0.15 applicable. Bharat Forge Ltd. 0.41 -0.42 Margin Deposits 20.48 Mindtree Ltd. 0.41 -0.42 Corporation Bank 0.70 Punjab National Bank 0.40 -0.40 Axis Bank 0.09 VOLATILITY MEASURES^ FUND BENCHMARK LIC Housing Finance Ltd. 0.40 -0.40 HDFC Bank Ltd. 4.09 Std. Dev (Annualised) 0.95 0.94 Apollo Tyres Ltd. 0.40 -0.40 Punjab National Bank 0.82 Balkrishna Industries Ltd. 0.36 -0.36 Bank Of Baroda 0.00 Sharpe Ratio 0.60 0.25 Bata India Ltd. 0.33 -0.34 Au Small Finance Bank Ltd. 1.59 Portfolio Beta 0.64 1.00 Federal Bank Ltd. 0.33 -0.33 Federal Bank Ltd. 4.90 R Squared 0.51 1.00 Siemens Ltd. 0.32 -0.32 Union Bank Of India 1.29 Variable Margin 7.00 Treynor 0.25 0.07 Hindustan Petroleum Corporation Ltd. 0.32 -0.32 Tata Chemicals Ltd. 0.31 -0.31 Jenson 0.12 NA Ashok Leyland Ltd. 0.30 -0.30 Repo 5.88 Portfolio Total 108.26 Portfolio Macauley Duration : 0.95 Years Escorts Ltd. 0.30 -0.30 Sun Tv Network Ltd. 0.30 -0.30 Cash / Net Current Assets/ (Liabilities) -8.26 Modified Duration : 0.93 Years Net Assets 100.00 Average Maturity : 0.99 Years SIP - If you had invested INR 10000 every month Gross Yield to Maturity (For Debt Component)* - Excluding Net Current Assets : 4.93% 1 Year 3 Year 5 Year 7 Year 10 Year Since Inception * Computed on the invested amount for debt portfolio. Total Amount Invested (Rs.) 120,000 NA NA NA NA 250,000 Total stock in Portfolio 110 Total Value as on Jan 31, 2021 (Rs.) 122,334 NA NA NA NA 262,968 Returns 3.65% NA NA NA NA 4.76% ^Risk-free rate based on the FBIL Overnight MIBOR rate of 3.47% as Total Value of B: Nifty 50 Arbitrage Index 121,112 NA NA NA NA 258,208 on Jan 29, 2021 B: Nifty 50 Arbitrage Index 1.74% NA NA NA NA 3.02% For calculation methodology please refer to Pg 64 Total Value of AB: Nifty 50 TRI 150,996 NA NA NA NA 308,358 AB: Nifty 50 TRI 51.56% NA NA NA NA 20.75% MINIMUM INVESTMENT/ (Inception date :18-Dec-2018) (First Installment date : 01-Jan-2019) MULTIPLES FOR NEW INVESTMENT Past performance may or may not be sustained in the future.
Load more

Recommended publications
  • Nominee List
    NOMINEE LIST Best financial reporting (large cap) Cipla Hindalco Industries Hindustan Unilever Infosys Kotak Mahindra Bank Mahindra & Mahindra Piramal Enterprises Tata Steel Vedanta Best financial reporting (small to mid-cap) CEAT Everest Industries Hikal Hindustan Foods IIFL Holdings KEC International Minda Industries Raymond The Phoenix Mills Zensar Technologies Best investor meetings (large cap) Bharti Airtel Hindustan Unilever Infosys Lupin Mahindra & Mahindra Piramal Enterprises Best investor meetings (mid-cap) Balkrishna Industries IIFL Holdings Mindtree RPG Group Sterlite Technologies The Phoenix Mills NOMINEE LIST Best investor meetings (small cap) Amber Enterprises India Equitas Holdings Greenlam Industries Music Broadcast Navin Fluorine International NOCIL Raymond Zensar Technologies Best investor relations officer (large cap) Bharti Airtel Komal Sharan Bharti Airtel Aparna Vyas Garg Bharti Infratel Surabhi Chandna Cipla Naveen Bansal HDFC Conrad D'Souza Hindustan Unilever Suman Hegde Infosys Sandeep Mahindroo Kotak Mahindra Bank Nimesh Kampani Lupin Arvind Bothra Best investor relations officer (small to mid-cap) CEAT Pulkit Bhandari Jindal Steel & Power Nishant Baranwal Motilal Oswal Financial Services Rakesh Shinde PNB Housing Finance Deepika Gupta Padhi Raymond J Mukund RPG Group Pulkit Bhandari Schneider Electric Infrastructure Vineet Jain The Phoenix Mills Varun Parwal NOMINEE LIST Best investor relations team (large cap) Bharti Airtel Cipla Hindustan Unilever Infosys Kotak Mahindra Bank Larsen & Toubro Infotech Power
    [Show full text]
  • Daiichi Sankyo Move Could Spark Copycats
    June 12, 2008 Daiichi Sankyo move could spark copycats Lisa Urquhart Daiichi Sankyo’s surprise move yesterday on Ranbaxy sparked not only a flurry of news about the $4.1bn deal, but has also got many in the market wondering who else might be on the shopping list of other big pharma companies looking to snap up an Indian generics firm. Those excited by the acquisition are pointing to the attractions of these companies, which include the increasing moves by governments to use generics to reduce healthcare costs, and in the case of Indian generic companies, their access to the fast growing, developing markets that big pharma has already expressed an interest in. With Ranbaxy now out of the picture, according to the EvaluatePharma’s Peer Group Analyzer Glenmark would be one of the most attractive in terms of future growth. The company may not be in the top three of the biggest Indian generics, but it is forecast to report an impressive 38% compound annual growth in unbranded generic sales in the five years to 2012. WW Unbranded Generic Sales WW annual sales ($m) CAGR (07-12) Market Rank 2007 2012 2007 2012 Glenmark Pharmaceuticals 244 1,211 38% 30 16 Wockhardt 357 764 16% 25 20 Lupin 303 647 16% 27 26 Aurobindo Pharma 165 334 15% 31 31 Matrix Laboratories 131 265 15% 34 35 Cipla 872 1,656 14% 14 11 Ranbaxy Laboratories 1,496 2,827 14% 9 6 Torrent Pharmaceuticals 300 543 13% 28 29 Piramal Healthcare 418 756 13% 20 21 Zydus Cadila 395 697 12% 22 24 Sun Pharmaceutical Industries 775 1,332 11% 15 15 Dr.
    [Show full text]
  • Risk Profile Performance Vs Benchmark Asset Mix Performance
    Performance Summary May 31, 2019 RICH Fund III ULIF 050 17/03/08 LRICH3 105 Fund Objective: Inception Date March 17, 2008 The objective of the fund is to generate ₹ superior long-term returns from a diversified Assets Invested 248.3 Million portfolio of equity and equity related instruments of companies operating in four Fatema Pacha important types of industries viz., Resources, Fund Manager(s) Funds Managed: 8 (8 Equity) Investment-related, Consumption-related and Human Capital leveraged industries. Benchmark BSE 200 NAV ₹ 26.0105 as on May 31, 2019 Return Risk Profile Fund Performance (As on May 31, 2019 ) Since 1 Month 6 Month 1 Year 2 Year 3 Year 4 Year 5 Year Inception Fund Return 1.62% 8.41% 3.84% 6.2% 9.95% 6.58% 10.13% 8.9% Benchmark Return 1.45% 7.78% 7.14% 9.41% 13.14% 8.98% 11.05% 9.31% Performance Vs Benchmark Asset Mix (As on May 31, 2019) 30.00 4% ₹ 9.28 Million 25.00 20.00 ) ₹ V in ( NA 15.00 10.00 5.00 Jan 10 Jan 12 Jan 14 Jan 16 Jan 18 96% ₹ 238.99 Million Period Equity and Equity related securities Minimum 80% RICH Fund III BSE 200 Debt, Money Market and Cash Maximum 20% Details are as per IRDAI Product Filing. Returns greater than 1 year are annualized. Past performance is not indicative of future performance. Performance Summary May 31, 2019 % of Invested Top 10 Sectors * Assets Financial and insurance activities 24.42% Computer programming consultancy and related activities 12.16% Infrastructure 9.13% Manufacture of coke and refined petroleum products 6.74% Manufacture of chemicals and chemical products 5.75% Manufacture of tobacco products 4.81% Manufacture of motor vehicles trailers and semi-trailers 3.71% Manufacture of pharmaceuticalsmedicinal chemical and botanical 2.98% products Manufacture of electrical equipment 2.44% Manufacture of other non-metallic mineral products 2.32% OTHERS 25.54% *As per IRDAI NIC industry classification Details are as per IRDAI Product Filing.
    [Show full text]
  • ANNUAL REPORT 2018-19 2 Notice
    CONTENTS Corporate Information ............................................................................................................ 02 Notice .................................................................................................................................... 03 Directors’ Report .................................................................................................................... 14 Annexures to Directors’ Report .............................................................................................. 25 Management Discussion and Analysis .................................................................................. 53 Business Responsibility Report ............................................................................................. 69 Report on Corporate Governance ......................................................................................... 80 Standalone Financial Statements .......................................................................................... 99 Consolidated Financial Statements ....................................................................................... 154 Financial Highlights - 5 years ................................................................................................. 212 CORPORATE INFORMATION BOARD OF DIRECTORS STATUTORY AUDITORS 1. Shri Sudhir Mehta B S R & Co. LLP Chairman Emeritus Chartered Accountants 2. Shri Samir Mehta Executive Chairman REGISTERED OFFICE 3. Shri Shailesh Haribhakti Torrent House, 4. Shri Haigreve
    [Show full text]
  • Annual Return
    FORM NO. MGT-7 Annual Return [Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of (other than OPCs and Small rule 11of the Companies (Management and Companies) Administration) Rules, 2014] Form language English Hindi Refer the instruction kit for filing the form. I. REGISTRATION AND OTHER DETAILS (i) * Corporate Identification Number (CIN) of the company Pre-fill Global Location Number (GLN) of the company * Permanent Account Number (PAN) of the company (ii) (a) Name of the company (b) Registered office address (c) *e-mail ID of the company (d) *Telephone number with STD code (e) Website (iii) Date of Incorporation (iv) Type of the Company Category of the Company Sub-category of the Company (v) Whether company is having share capital Yes No (vi) *Whether shares listed on recognized Stock Exchange(s) Yes No Page 1 of 17 (a) Details of stock exchanges where shares are listed S. No. Stock Exchange Name Code 1 2 (b) CIN of the Registrar and Transfer Agent Pre-fill Name of the Registrar and Transfer Agent Registered office address of the Registrar and Transfer Agents (vii) *Financial year From date 01/04/2020 (DD/MM/YYYY) To date 31/03/2021 (DD/MM/YYYY) (viii) *Whether Annual general meeting (AGM) held Yes No (a) If yes, date of AGM 27/07/2021 (b) Due date of AGM 30/09/2021 (c) Whether any extension for AGM granted Yes No II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY *Number of business activities 1 S.No Main Description of Main Activity group Business Description of Business Activity % of turnover Activity Activity of the group code Code company C C6 III.
    [Show full text]
  • In the United States District Court for the District of New Jersey
    Case 1:19-md-02875-RBK-JS Document 121 Filed 06/17/19 Page 1 of 130 PageID: 1141 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY IN RE: VALSARTAN PRODUCTS LIABILITY LITIGATION No. 1:19-md-2875-RBK Hon. Robert Kugler Hon. Joel Schneider Jury Trial Demanded Consolidated Amended Class Action Complaint CONSOLIDATED AMENDED ECONOMIC LOSS CLASS ACTION COMPLAINT 1. COME NOW, the Consumer and Third Party Payor (“TPP”) Plaintiffs (collectively the “Class Plaintiffs”), who file this Consolidated Amended Economic Loss Class Action Complaint (“Master Class Complaint”)1 against the below-enumerated Defendants. I. INTRODUCTION 2. This case arises from adulterated, misbranded, and unapproved valsartan- containing drugs (“VCDs”) that were designed, manufactured, marketed, distributed, packaged, and sold by Defendants (identified and defined infra at Part II.C-H) in the United States, and which have been and remain the subject of one of the largest ongoing contaminated drug recalls ever in the United States. These VCDs are non-merchantable, and are not of the quality represented by Defendants named herein. 3. Valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the registered listed drugs (“RLDs”) Diovan® (“DIOVAN”) and Diovan HCT® (“DIOVAN HCT”), respectively. Amlodipine-valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the RLDs of Exforge® (“EXFORGE”) and 1 This is one of three master complaints being filed in this multi-district litigation. The filing of three master complaints is to streamline the pleadings and issues for the parties’ mutual convenience only. Consumer Class Plaintiffs do not waive any claims that are not raised herein, or that are asserted in another master complaint.
    [Show full text]
  • In Every Relationship Titan Company Limited
    IN EVERY RELATIONSHIP TITAN COMPANY LIMITED ANNUAL REPORT 2017-18 Announcement We are taking our first steps to move ANNUAL REPORT to Integrated Reporting in line with our continuous commitment to 2017-18 voluntarily disclose more information to our stakeholders on all aspects of our business. Accordingly, we have introduced key content elements of Integrated Reporting <IR> aligned to the Integrated Reporting Council Framework (IIRC) and as per SEBI’s circular dated 6 February 2017. We will add more IR content elements over the years as we move towards a complete <IR>. It is possible that some IR related data Contents are management estimates. Reporting Principle Financial Statements About TItaN The financial and statutory data presented in this Report is in line with 02 Financial Highlights Standalone Financial the requirements of the 03 Operating Context Statements Companies Act, 2013 (including 04 The Titan Journey 116 Independent the Rules made thereunder), Indian 06 Titan Today Auditor’s Report Accounting Standards, the Securities 08 Business Review 112 Balance Sheet and Exchange Board of India 18 Journey towards 113 Profit & Loss Account (Listing Obligations and Disclosure Integrated Reporting 115 Cash Flow Statement Requirements) Regulations, 2015 and 26 Engaging with 117 Significant accounting the Secretarial Standards. our Stakeholders policies 28 Outlook and Opportunities 130 Notes to Financial The non-financial section of the Report 30 People and Culture Statements is guided by the framework of the 31 Leadership Development International Integrated Reporting 32 Purity of Intent Consolidated Financial Council (IIRC), Securities and Exchange Statements 34 Board Of Directors Board of India and Principles of 130 AOC-1 36 Awards National Voluntary Guidelines on 169 Independent Auditor’s social, environmental and economic Report responsibilities of business.
    [Show full text]
  • Marketgrader India All-Cap Growth Leaders Index
    Fact Sheet MarketGrader MarketGrader India All-Cap Growth Leaders Index RESEARCH & INDEXES The MarketGrader India All-Cap Growth Leaders Index consists of the 80 most fundamentally sound companies with the best growth prospects in India, whose shares are listed in the country’s national exchanges or in the United States. Its objective is to give investors access to the best companies in the world’s fastest growing large economy without overpaying for their shares. Constituents are selected across all market cap segments and all economic sectors after they have passed rigorous size and liquidity filters. Index Rules Performance Investable Universe CumulativeIndia Growth Leaders Total Return, Jan. 2008 - Jul. 2021 All data as of July 30, 2021 All companies domiciled in India that have 175% received a MarketGrader Score consistently for at least six months, whose shares are 150% listed on the National Stock Exchange, the 125% Bombay Stock Exchange or on U.S. national 100% exchanges. 75% Regulatory Requirements 50% Stocks are ineligible for Index selection if 25% they are included in the ‘Red Flag List,’ 0% maintained and published by the National Securities Depository Limited (NDSL) of India, -25% or on the ‘Breach List,’ maintained by the -50% Central Depository Services (India) Limited 07/30/21 -75% (CDSL), both of which govern foreign own- 12/31/07 12/31/08 12/31/09 12/31/10 12/30/11 12/31/12 12/31/13 12/31/14 12/31/15 12/30/16 12/29/17 12/31/18 12/31/19 12/31/20 ership limits of Indian securities.
    [Show full text]
  • Company Reliance Industries Limited Tata Consultancy Services
    Top 1000 Private Sector Companies (Rank-wise List) Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited Grasim Industries Limited Jet Airways (India) Ltd. Sun Pharmaceuticals Industries Ltd Cipla Ltd. Gujarat Ambuja Cements Ltd. Videsh Sanchar Nigam Limited The Tata Power Company Limited Sterlite Industries (India) Ltd. Associated Cement Companies Ltd. Nestlé India Ltd. Hindustan Zinc Limited GlaxoSmithKline Pharmaceuticals Limited Siemens India Ltd. Motor Industries Company Limited Mahindra & Mahindra Limited UTI Bank Ltd. Zee Telefilms Limited Bharat Forge Limited ABB Limited i-Flex Solutions Ltd. Dr. Reddy's Laboratories Ltd. Nicholas Piramal India Limited Kotak Mahindra Bank Limited Reliance Capital Ltd. Ultra Tech Cement Ltd. Patni Computer Systems Ltd. Wockhardt Limited Indian Petrochemicals Corporation Limited Biocon India Limited Essar Oil Limited. Asian Paints Ltd. Dabur India Limited Jaiprakash Associates Limited JSW Steel Limited Tata Chemicals Limited Tata Tea Limited Tata Teleservices (Maharashtra) Limited The Indian Hotels Co. Ltd. Glenmark Pharmaceuticals Limited NIRMA Limited Jindal Steel & Power Ltd HCL Infosystems Ltd. Cadila Healthcare Limited Colgate-Palmolive (India) Limited The Great Eastern Shipping Company Limited Aventis Pharma India Ltd Ashok Leyland Limited Pantaloon Retail (India) Limited Indian Rayon And Industries Limited Financial Technologies (India) Ltd United Phosphorus Limited Matrix Laboratories Limited Sesa Goa Limited Lupin Ltd Cummins India Limited Crompton Greaves Limited.
    [Show full text]
  • John Hancock Emerging Markets Fund
    John Hancock Emerging Markets Fund Quarterly portfolio holdings 5/31/2021 Fund’s investments As of 5-31-21 (unaudited) Shares Value Common stocks 98.2% $200,999,813 (Cost $136,665,998) Australia 0.0% 68,087 MMG, Ltd. (A) 112,000 68,087 Belgium 0.0% 39,744 Titan Cement International SA (A) 1,861 39,744 Brazil 4.2% 8,517,702 AES Brasil Energia SA 14,898 40,592 Aliansce Sonae Shopping Centers SA 3,800 21,896 Alliar Medicos A Frente SA (A) 3,900 8,553 Alupar Investimento SA 7,050 36,713 Ambev SA, ADR 62,009 214,551 Arezzo Industria e Comercio SA 1,094 18,688 Atacadao SA 7,500 31,530 B2W Cia Digital (A) 1,700 19,535 B3 SA - Brasil Bolsa Balcao 90,234 302,644 Banco Bradesco SA 18,310 80,311 Banco BTG Pactual SA 3,588 84,638 Banco do Brasil SA 15,837 101,919 Banco Inter SA 3,300 14,088 Banco Santander Brasil SA 3,800 29,748 BB Seguridade Participacoes SA 8,229 36,932 BR Malls Participacoes SA (A) 28,804 62,453 BR Properties SA 8,524 15,489 BrasilAgro - Company Brasileira de Propriedades Agricolas 2,247 13,581 Braskem SA, ADR (A) 4,563 90,667 BRF SA (A) 18,790 92,838 Camil Alimentos SA 11,340 21,541 CCR SA 34,669 92,199 Centrais Eletricas Brasileiras SA 5,600 46,343 Cia Brasileira de Distribuicao 8,517 63,718 Cia de Locacao das Americas 18,348 93,294 Cia de Saneamento Basico do Estado de Sao Paulo 8,299 63,631 Cia de Saneamento de Minas Gerais-COPASA 4,505 14,816 Cia de Saneamento do Parana 3,000 2,337 Cia de Saneamento do Parana, Unit 8,545 33,283 Cia Energetica de Minas Gerais 8,594 27,209 Cia Hering 4,235 27,141 Cia Paranaense de Energia 3,200
    [Show full text]
  • Revision in Market Lot of Derivative Contracts on Individual Stocks
    Department : FUTURES & OPTIONS Download Ref No: NSE/FAOP/45895 Date : September 30, 2020 Circular Ref. No: 87/2020 All Members, Revision in Market Lot of Derivative Contracts on Individual Stocks In pursuance of SEBI guidelines for periodic revision of lot sizes for derivatives contracts specified in the SEBI circular CIR/MRD/DP/14/2015 dated July 13, 2015, the market lots of derivatives contracts shall be revised as follows: Sr. Underlying whose Derivative Count of Annexure No Effective date contract size shall be Underlying Number October 30, 2020 (for Nov 1 Revised Downwards 15 1 2020 & later expiries) 2 Revised Upwards 12 October 30, 2020 (for Jan 2 2021 & later expiries) 3 Unchanged 108 - 3 Revised Downwards but new October 30, 2020 (for Jan 4 lot size is not a multiple of old 1 4 2021 & later expiries) lot size To avoid operational complexities, in case of Annexure 2 and 4 above, following will be applicable: 1. Only the far month contract i.e. January 2021 expiry contracts will be revised for market lots. Contracts with maturity of November 2020 and December 2020 would continue to have the existing market lots. All subsequent contracts (i.e. January 2021 expiry and beyond) will have revised market lots. 2. The day spread order book will not be available for the combination contract of Dec 2020 – Jan 2021 expiry. For the purpose of the computation, the average of the closing price of the underlying has been taken for one month period of September 1st – September 30th 2020. This circular shall come into effect from October 30, 2020.
    [Show full text]
  • Balkrishna Industries (BALIND)
    Balkrishna Industries (BALIND) CMP: | 1,450 Target: | 1,700 (17%) Target Period: 12 months BUY November 8, 2020 Robust performance, firm growth prospects lie ahead Balkrishna Industries (BIL) reported stellar Q2FY21 results. Standalone revenue was at | 1,579 crore (up 47% YoY), amid ~36% rise in volumes to 61,224 MT. Margins rose 903 bps YoY to a near five-year high of 34% amid Particulars 494 bps gross margin expansion and savings in employee costs and other P articular ₹ crore expenses. Consequent PAT came in at | 340 crore (up 16.7% YoY). BIL Market Capitalization 28,031 Update declared second interim dividend of | 4/share (record date: November 14). Total Debt (FY20) 861.2 Healthy demand, market share gains keep outlook constructive C ash & Inv (F Y 20) 1,108.6 E V (₹ C rore) 27,783.6 Result BIL is the market leader in the niche export-oriented off-highway tyre (OHT) 52 week H/L (₹) 1515 / 678 segment. As of H1FY21, agri, OTR demand formed 64%, 33%, respectively, E quity capital (₹ crore) 38.7 Face value (₹) 2.0 of end user applications, while in term of geographies Europe (51%), India (23%), North America (14%) constituted its major markets. Replacement demand formed 71% of overall pie. Demand prospects for its products Price Chart remain healthy, particularly on the Europe agri side, where it has gained 1500 14,000 market share in aftermarket amid overall positivity for the industry. The 12,000 company continues to introduce new SKUs (average of ~100 every year) 1000 10,000 8,000 and engage in brand building (via ad spends) in order to gain incremental 6,000 500 4,000 market share.
    [Show full text]